Transforming Mass Spectrometry Workflows For New Psychoactive Substances (NPS) Analysis With Terry Bates
At ASMS 2025, the Technology Networks team caught up with Terry Bates, Founder and CEO, Quantera Analytical, to discuss recent technological advances in mass spectrometry. He explains how these developments allow for a more agile response to current challenges in drug analysis, including the rapid emergence and complexity of new psychoactive substances (NPS).
Watch the full video to learn more exciting features of this new technology.